Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

May 1, 2021

Study Completion Date

May 1, 2021

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Orteronel

Trial Locations (10)

20817

Center for Cancer and Blood Disorders, Bethesda

30501

Northeast Georgia Medical Center, Gainesville

37203

Tennessee Oncology PLLC, Nashville

37404

Tennessee Oncology PLLC, Chattanooga

40207

Baptist Hospital East, Louisville

47802

Hope Cancer Center, Terre Haute

49503

Cancer Research Consortium of West Michigan, Grand Rapids

73505

Cancer Centers of SW Oklahoma, Lawton

76104

Center for Cancer and Blood Disorders, Fort Worth

06520

Yale School of Medicine, New Haven

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER

NCT01990209 - Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) | Biotech Hunter | Biotech Hunter